Cyclin Pathway Genomic Alterations Across 190,247 Solid Tumors: Leveraging Large‐Scale Data to Inform Therapeutic Directions

Multifaceted p21 in carcinogenesis, stemness of tumor and tumor therapy

(2020) Bo-Duan Xiao et al.   World Journal of Stem Cells

Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up

(2019) H. S. Rugo et al.   BREAST CANCER RESEARCH AND TREATMENT

Cyclin E1 Expression and Palbociclib Efficacy in Previously Treated Hormone Receptor–Positive Metastatic Breast Cancer

(2019) Nicholas C. Turner et al.   JOURNAL OF CLINICAL ONCOLOGY

Allosteric Regulation of Cyclin-B Binding by the Charge State of Catalytic Lysine in CDK1 Is Essential for Cell-Cycle Progression

(2019) Shaunak Deota et al.   JOURNAL OF MOLECULAR BIOLOGY

Renal medullary carcinomas depend upon SMARCB1 loss and are sensitive to proteasome inhibition

(2019) Andrew L Hong et al.   eLife

Practical treatment strategies and future directions after progression on CDK4/6 inhibition and endocrine therapy in advanced HR+/HER2- breast cancer

(2019) Sarah Sammons et al.   Clinical Breast Cancer

Drivers of AR indifferent anti-androgen resistance in prostate cancer cells

(2019) Florian Handle et al.   Scientific Reports

TMPRSS2-ERG controls luminal epithelial lineage and antiandrogen sensitivity inPTENandTP53-mutated prostate cancer

(2018) Alexandra M Blee et al.   CLINICAL CANCER RESEARCH

Comprehensive Genomic Sequencing of Urothelial Tumors Identifies Rare SMARCB1 (INI-1)–Deficient Carcinomas of the Urinary System

(2018) Sumati Gupta et al.   Clinical Genitourinary Cancer

Soft tissue sarcomas in the precision medicine era: new advances in clinical practice and future perspectives

(2018) Giuseppe Badalamenti et al.   Radiologia Medica

Cyclin-dependent kinase 4/6 inhibitors in hormone receptor-positive early breast cancer: preliminary results and ongoing studies

(2018) Dorota Kwapisz   Breast Cancer

The genetic landscape and clonal evolution of breast cancer resistance to palbociclib plus fulvestrant in the PALOMA-3 trial

(2018) Ben O'Leary et al.   Cancer Discovery

Phosphatidylinositol 3-kinase pathway genomic alterations in 60,991 diverse solid tumors informs targeted therapy opportunities

(2018) Sherri Z. Millis et al.   CANCER

YAP1-mediated CDK6 Activation Confers Radiation Resistance in Esophageal Cancer - Rationale for the combination of YAP1 and CDK4/6 inhibitors in Esophageal Cancer

(2018) Fan Li et al.   CLINICAL CANCER RESEARCH

Molecular mechanisms of resistance to CDK4/6 inhibitors in breast cancer: A review

(2018) Kamal Pandey et al.   INTERNATIONAL JOURNAL OF CANCER

MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer

(2017) Matthew P. Goetz et al.   JOURNAL OF CLINICAL ONCOLOGY

CDK4/6 inhibitor-SHR6390 exerts potent antitumor activity in esophageal squamous cell carcinoma by inhibiting phosphorylated Rb and inducing G1 cell cycle arrest

(2017) Jiayuan Wang et al.   Journal of Translational Medicine

CDK4/6 Therapeutic Intervention and Viable Alternative to Taxanes in CRPC

(2017) James P. Stice et al.   MOLECULAR CANCER RESEARCH

Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients

(2017) Ahmet Zehir et al.   NATURE MEDICINE

Clinical Benefit in Response to Palbociclib Treatment in Refractory Uterine Leiomyosarcomas with a Common CDKN2A Alteration

(2017) Julia A. Elvin et al.   ONCOLOGIST

Targeting Cyclin-Dependent Kinases in Synovial Sarcoma: Palbociclib as a Potential Treatment for Synovial Sarcoma Patients

(2016) Myrella Vlenterie et al.   ANNALS OF SURGICAL ONCOLOGY

Targeting CDK4/6 in patients with cancer

(2016) Erika Hamilton et al.   CANCER TREATMENT REVIEWS

Balanced Translocations Disrupting SMARCB1 Are Hallmark Recurrent Genetic Alterations in Renal Medullary Carcinomas

(2016) Julien Calderaro et al.   EUROPEAN UROLOGY

Gene of the month:SMARCB1

(2016) Sangeetha N Kalimuthu et al.   JOURNAL OF CLINICAL PATHOLOGY

Cell-Cycle Gene Alterations in 4,864 Tumors Analyzed by Next-Generation Sequencing: Implications for Targeted Therapeutics

(2016) Teresa Helsten et al.   MOLECULAR CANCER THERAPEUTICS

Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer

(2016) Gabriel N. Hortobagyi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Implications of Genetic and Epigenetic Alterations of CDKN2A (p16 INK4a ) in Cancer

(2016) Ran Zhao et al.   EBioMedicine

Cyclin-dependent kinase pathway aberrations in diverse malignancies: clinical and molecular characteristics

(2015) Shumei Kato et al.   CELL CYCLE

Impact of Precision Medicine in Diverse Cancers: A Meta-Analysis of Phase II Clinical Trials

(2015) Maria Schwaederle et al.   JOURNAL OF CLINICAL ONCOLOGY

The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study

(2015) Richard S Finn et al.   LANCET ONCOLOGY

Cyclin alterations in diverse cancers: Outcome and co-amplification network

(2015) Maria Schwaederle et al.   Oncotarget

RB1 in cancer: Different mechanisms of RB1 inactivation and alterations of pRb pathway in tumorigenesis

(2013) Riccardo Di Fiore et al.   JOURNAL OF CELLULAR PHYSIOLOGY

Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing

(2013) Garrett M Frampton et al.   NATURE BIOTECHNOLOGY

Molecular Pathways: Targeting Mdm2 and Mdm4 in Cancer Therapy

(2012) Q. Li et al.   CLINICAL CANCER RESEARCH

Mechanisms of Endocrine Resistance in Breast Cancer

(2010) C. Kent Osborne et al.   Annual Review of Medicine